Document is current

Any future updates will be listed below

Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

Crossref DOI link: https://doi.org/10.1186/S40064-015-1233-Y

Published Online: 2015-09-21

Published Print: 2015-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

About CrossMark